EyeCon 2026 Banner
|Articles|May 1, 2007

Bevacizumab appears safe for neovascular AMD in short term

The short-term clinical experience with intravitreal bevacizumab (Avastin, Genentech) supports growing perception that treatment is safe and effective for neovascular age-related macular degeneration.


Latest CME